Navigation Links
MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

Company Provides Revised Timing on Interim Celgosivir Viral Kinetics Study

Data

VANCOUVER and SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases will present at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference being held at the New York Palace Hotel in New York, NY on November 5-7, 2007. Jim DeMesa, M.D., President & CEO is scheduled to present on Monday, November 5 at 4:45 p.m. EST in the Holmes I room.

As part of an overall corporate update, Dr. DeMesa will highlight the following:

- Omigard(TM) - a partnered Phase III product candidate for the

prevention of catheter-related infections

- Celgosivir - a Phase II product candidate for treating chronic

hepatitis C virus infections

- CLS001 - recent Phase II results from our partnered topical treatment

for rosacea.

Additionally, interim 4-week data expected in October from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection are delayed due to sample analysis not being completed at a contract research organization. Results will be reported when available, which is now anticipated to be in November.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... recently approved the Promega PowerPlex 16 HS Sys...nerating DNA records for the National DNA Index Sy...PRWEB) -- The FBI recently approved the Promega P...s participating in, or generating DNA records for,...tly contains more than seven million profiles and ...
(Date:11/24/2009)... 24 Shire plc (LSE: SHP,...eutical company, today,announced that it has submi...laglucerase alfa, the company,s enzyme replacement...1 Gaucher disease. This is the third marketing,app...itted, with previous,submissions in the United Sta...
(Date:11/24/2009)...November 24 Health Robotics today ...venture with a group of selected,investors. This r...under the,name Health Robotics Canada, Inc. and wi....v. Room of the Future concept, which includes the...i.v.SOFT(TM), and OMM(TM).,Health Robotics Canada ...
(Date:11/24/2009)... Cell Therapeutics, Inc. ...nt at the 21st Annual Piper Jaffray Health Care Co..., 2009, at the New York Palace Hotel. ,, CTI ...Eastern Time in Holmes 1 (4th Floor). A live audio...t www.celltherapeutics.com , and it will also be ...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3
..., May 19 MedClean Technologies, Inc. (OTC Bulleti...ed a private offer to exchange all of the Company,...tial Exercise Dates between July 11, 2008 and Augu... Common Stock Purchase Warrants, with a new lower ...ares of our common stock, par value $0.0001 per sh...
...., May 19 In an eleventh-hour attempt to smear T...Y ) has issued a press release claiming that there...r. Richard Rosenbloom, a key staff member of a sub...a group of dissident shareholders who have offered...or election at the annual meeting scheduled for We...
...hina, May 19 /PRNewswire-Asia-FirstCall/ -- China ...the Company") (Nasdaq: CSKI ), a leading,fully i...e-counter drugs in,the People,s Republic of China ...rhouse Coopers ("PWC") to assist the Company in co...equirements of Sarbanes-Oxley Act Section 404,("SO...
Other Biology Technology:MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 2MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 3MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants 4In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program 2China Sky One Medical, Inc. Appoints Pricewaterhouse Coopers to Help Develop a SOX 404 Compliance Program 3
(Date:11/26/2009)..., Heidelberg, 27 November 2009 What are the ba...ts required to produce a cell that can survive on ...a cell, and understand how an entire organism func...tions that scientists in a partnership between the...eidelberg, Germany, and the Centre de Regulacio Ge...
(Date:11/25/2009)... On September 11, firefighters, police officers an...rt in the World Trade Center complex. They battled...earched for survivors, tackled fires and evacuated...tained an estimated 17,000 people. And making thei...cations: frightened workers and their relatives ja...
(Date:11/25/2009)..., LA JOLLA, CAWhen you eat may be just as vital t...t the Salk Institute for Biological Studies. Their...g and waning of thousands of genes in the liverthe...d by food intake and not by the body,s circadian c...ng time determines the activity of a large number ...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3Oxygen Biotherapeutics Inc to Present at Investment Conferences in New York and Zurich 13695 1Oxygen Biotherapeutics Inc to Present at Investment Conferences in New York and Zurich 13695 2NIAID Awards New Grant to Expand Studies of Peregrines Anti PS Antibodies to Treat Viral Hemorrhagic Fevers 55384 1NIAID Awards New Grant to Expand Studies of Peregrines Anti PS Antibodies to Treat Viral Hemorrhagic Fevers 55384 2NIAID Awards New Grant to Expand Studies of Peregrines Anti PS Antibodies to Treat Viral Hemorrhagic Fevers 55384 3NIAID Awards New Grant to Expand Studies of Peregrines Anti PS Antibodies to Treat Viral Hemorrhagic Fevers 55384 4NIAID Awards New Grant to Expand Studies of Peregrines Anti PS Antibodies to Treat Viral Hemorrhagic Fevers 55384 5American Brain Tumor Association Statement on the Death of U S Senator Edward M Kennedy 55380 1
...reasing attention given to the potential of biocha... wood) to serve as a long term sink of carbon in t...nd breaks down extremely slowly, persisting in soi...estion being seriously considered by policy makers... quantities and stored in soils. This would in tur...
... in French . , Canadian, French and British re...rols the variability of blood glucose levels in pe...because high blood glucose levels in otherwise hea... and higher mortality rates. The results will be p...l Science. , The research was conducted by Dr. P...
...Texas The first year of ConocoPhillips [NYSE:COP]...a State University (ISU) has supported 26 research...orations to further diversify Americas sources of ...ocoPhillips, the third-largest integrated energy c...n to begin 14 research projects at ISU in 2007. Th...
Other Biology News:Limitations of charcoal as an effective carbon sink 2Genetic breakthrough explains dangerously high blood glucose levels 2Genetic breakthrough explains dangerously high blood glucose levels 3Iowa State-ConocoPhillips collaboration advances 26 research projects in first year 2
...CC1041 is a recombinant 177 amino acid polypeptide... human MT1-MMP. Produced by activation of a recom... coli periplasm. SPECIFIC ACTIVITY:The specific a..., where 1 U is the activity that hydrolyzes 1 mol ...
...The EC570-90 is a compact, lightweight, high curre...ts or 2500 milliamps. It is an excellent choice fo... is also ideal for all types of electroblotting ap...t to automatically end a run and wil automatically...
Anti-Interferon-beta (IFNb) Monoclonal Antibody, Unconjugated from CHEMICON
...For use in Refrigerated Vapor Trap Models RVT100, ...urce (UVS) Models UVS400, UVS400A and UVS800DDA.,...licone polymer suitable for use for temperatures r... has excellent thermal stability and does not evap...
Biology Products: